Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects previously randomized to Pfizer clinical study B5301001.~* Subjects must be able to tolerate up to a 3 hour scar revision surgery under sedation and local anesthesia.~Exclusion Criteria:~* Pregnant female subject; breastfeeding female subjects; male subjects with partners currently pregnant.~* Any previous history of intolerable adverse reactions to PF-06473871, such as serious adverse events attributed to study drug or having been withdrawn due to AE in prerequisite study B5301001.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 57 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
- Group 2 (Type: EXPERIMENTAL): The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).

Based on this trial design, predict the completion outcome and termination type (if applicable).